- Home
- OSCR vs KNSA Comparison
OSCR vs KNSA Comparison
Compare OSCR & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSCR | KNSA |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.4B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | OSCR | KNSA |
|---|---|---|
| Price | $13.60 | $46.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $17.00 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 7.3M | 580.2K |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | ★ $11,701,427,000.00 | $677,564,000.00 |
| Revenue This Year | $63.73 | $38.01 |
| Revenue Next Year | $5.40 | $17.42 |
| P/E Ratio | ★ N/A | $62.41 |
| Revenue Growth | 27.50 | ★ 60.09 |
| 52 Week Low | $11.20 | $18.26 |
| 52 Week High | $23.80 | $49.12 |
Technical Indicators
Market Signals| Indicator | OSCR | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 57.86 |
| Support Level | $12.47 | $40.47 |
| Resistance Level | $15.71 | $49.12 |
| Average True Range (ATR) | 0.71 | 2.17 |
| MACD | 0.13 | 0.05 |
| Stochastic Oscillator | 41.87 | 71.13 |
Price Performance
Historical ComparisonAbout OSCR Oscar Health Inc.
Oscar Health Inc is a healthcare technology company built around a full stack technology platform and a relentless focus on serving its members. It offers Individual & Family plans and health technology solutions that power the healthcare industry. Oscar operates as one segment to sell insurance to individuals, families and employees through the federal and state-run healthcare exchanges formed in conjunction with the Patient Protection and Affordable Care Act (ACA) and leverages its technology platform to provide services via its Oscar offering.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.